Novel central nervous system drug delivery systems

Chemical Biology and Drug Design

Volumn 83, Issue 5, 2014, Pages 507-520

  Stockwell, Jocelyn ^a   Abdi, Nabiha ^a   Lu, Xiaofan ^a   Maheshwari, Oshin ^a   Taghibiglou, Changiz ^a  

^a 2D01 Health Sciences ^*  (Canada)

Author keywords

drug delivery ADMET; drug design; drug discovery; ligands (agonist antagonist); nanotechnology (drug discovery); receptor

Indexed keywords

CELL PENETRATING PEPTIDE; GLUCOSE TRANSPORTER 1; MAGNETIC NANOPARTICLE; NANOPARTICLE; POLYMERIC NANOPARTICLE; PRODRUG; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; LIPID; MOLECULAR LIBRARY;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; HUMAN; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; THERMODYNAMICS; ULTRASOUND; CHEMISTRY; METABOLISM; MOLECULAR LIBRARY;

BLOOD-BRAIN BARRIER; CELL-PENETRATING PEPTIDES; CENTRAL NERVOUS SYSTEM; DRUG CARRIERS; HUMANS; LIPIDS; NANOPARTICLES; PRODRUGS; SMALL MOLECULE LIBRARIES;

EID: 84899476397     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12268     Document Type: Review

References (97)

1. Brethour M.K., Nyström K.V., Broughton S., Kiernan T.E., Perez A., Handler D., Swatzell V., Yang J.J., Starr M., Seagraves K.B., (2012) Controversies in acute stroke treatment. AACN Adv Crit Care; 23: 158.
2. Gabathuler R., (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis; 37: 48-57.
3. Pathan S.A., Iqbal Z., Zaidi S., Talegaonkar S., Vohra D., Jain G.K., Azeem A., Jain N., Lalani J.R., Khar R.K., (2009) CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul; 3: 71-89.
4. Banks W.A., (2010) Blood-brain barrier as a regulatory interface. Forum Nutr; 63: 102-110.
5. Banks W.A., (2012) Brain meets body: the blood-brain barrier as an endocrine interface. Endocrinology; 153: 4111-4119.
6. Abbott N.J., Patabendige A.A.K., Dolman D.E.M., Yusof S.R., Begley D.J., (2010) Structure and function of the blood-brain barrier. Neurobiol Dis; 37: 13-25.
7. Abbott N.J., (2005) Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol; 25: 5-23. (Pubitemid 40558582)
8. Banks W.A., (2009) Characteristics of compounds that cross the blood-brain barrier. BMC Neurol; 9 (Suppl 1): S3.
9. Bellavance M.A., Blanchette M., Fortin D., (2008) Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J; 10: 166-177.
10. Banks W.A., (2008) Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers; 90: 589-594.
11. Pardridge W.M., (2012) Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab; 14: 338-348.
12. Ballabh P., Braun A., Nedergaard M., (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis; 16: 1-13. (Pubitemid 38569790)
13. Grieb P., Forster R., Strome D., Goodwin C., Pape P., (1985) O2 exchange between blood and brain tissues studied with 18O2 indicator-dilution technique. J Appl Physiol; 58: 1929-1941. (Pubitemid 15013854)
14. Pasha S., Gupta K., (2010) Various drug delivery approaches to the central nervous system. Expert Opin Drug Deliv; 7: 113-135.
15. Parveen S., Misra R., Sahoo S.K., (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed Nanotechnol Biol Med; 8: 147-166.
16. Kabanov A., Batrakova E., (2004) New technologies for drug delivery across the blood-brain barrier. Curr Pharm Des; 10: 1355.
17. Murad G.J.A., Walbridge S., Morrison P.F., Garmestani K., Degen J.W., Brechbiel M.W., Oldfield E.H., Lonser R.R., (2006) Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res; 12: 3145-3151. (Pubitemid 43837363)
18. McDannold N., Arvanitis C.D., Vykhodtseva N., Livingstone M.S., (2012) Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res; 72: 3652-3663.
19. Rogawski M.A., (2009) Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics; 6: 344-351.
20. Choi M., Ku T., Chong K., Yoon J., Choi C., (2011) Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability. Proc Natl Acad Sci U S A; 108: 9256-9261.
21. Yin D., Zhai Y., Gruber H., Ibanez C., Robbins J., Kells A., Kasahara N., Forsayeth J., Jolly D., Bankiewicz K., (2013) Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model. Cancer Gene Ther; 20: 336-341.
22. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H., (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A; 91: 2076-2080. (Pubitemid 24092045)
23. Stiles D.K., Zhang Z., Ge P., Nelson B., Grondin R., Ai Y., Hardy P., Nelson P.T., Guzaev A.P., Butt M.T., (2012) Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol; 233: 463-471.
24. Song D.K., Lonser R.R., (2008) Convection-enhanced delivery for the treatment of pediatric neurologic disorders. J Child Neurol; 23: 1231-1237.
25. Allhenn D., Boushehri M.A., Lamprecht A., (2012) Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm; 436: 299-310.
26. Chen K.S., Mitchell D.A., (2012) Monoclonal antibody therapy for malignant glioma. Adv Exp Med Biol; 746: 121-141.
27. Mehta A.I., Choi B.D., Ajay D., Raghavan R., Brady M., Friedman A.H., Pastan I., Bigner D.D., Sampson J.H., (2012) Convection enhanced delivery of macromolecules for brain tumors. Curr Drug Discov Technol; 9: 305-310.
28. Saito R., Tominaga T., (2012) Convection-enhanced delivery: from mechanisms to clinical drug delivery for diseases of the central nervous system. Neurol Med Chir (Tokyo); 52: 531-538.
29. Solorio L., Patel R.B., Wu H., Krupka T., Exner A.A., (2010) Advances in image-guided intratumoral drug delivery techniques. Ther Deliv; 1: 307-322.
30. Bidros D.S., Liu J.K., Vogelbaum M.A., (2010) Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol; 6: 117-125.
31. Debinski W., Tatter S.B., (2009) Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother; 9: 1519-1527.
32. Barua N.U., Miners J.S., Bienemann A.S., Wyatt M.J., Welser K., Tabor A.B., Hailes H.C., Love S., Gill S.S., (2012) Convection-enhanced delivery of neprilysin: a novel amyloid-beta-degrading therapeutic strategy. J Alzheimers Dis; 32: 43-56.
33. Miners J.S., Barua N., Kehoe P.G., Gill S., Love S., (2011) Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol; 70: 944-959.
34. Lam M.F., Thomas M.G., Lind C.R., (2011) Neurosurgical convection-enhanced delivery of treatments for Parkinson's disease. J Clin Neurosci; 18: 1163-1167.
35. Haar P.J., Broaddus W.C., Chen Z.J., Fatouros P.P., Gillies G.T., Corwin F.D., (2010) Quantification of convection-enhanced delivery to the ischemic brain. Physiol Meas; 31: 1075-1089.
36. Sampson J.H., Akabani G., Archer G.E., Berger M.S., Coleman R.E., Friedman A.H., Friedman H.S., Greer K., Herndon J.E., Kunwar S., (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-oncology; 10: 320-329.
37. Zhou J., Atsina K.B., Himes B.T., Strohbehn G.W., Saltzman W.M., (2012) Novel delivery strategies for glioblastoma. Cancer J; 18: 89-99.
38. Jacobs A., Voges J., Reszka R., Lercher M., Gossmann A., Kracht L., Kaestle C., Wagner R., Wienhard K., Heiss W., (2001) Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet; 358: 727-729. (Pubitemid 32823405)
39. Gasior M., Tang R., Rogawski M.A., (2013) Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins A and B into the amygdala in rats. J Pharmacol Exp Ther; 348: 1-29.
40. Kunwar S., Chang S., Westphal M., Vogelbaum M., Sampson J., Barnett G., Shaffrey M., Ram Z., Piepmeier J., Prados M., (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-oncology; 12: 871-881.
41. Tsutsui J.M., Xie F., Porter R.T., (2004) The use of microbubbles to target drug delivery. Cardiovasc Ultrasound; 2: 23.
42. Laquintana V., Trapani A., Denora N., Wang F., Gallo J.M., Trapani G., (2009) New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv; 6: 1017-1032.
43. Hynynen K., (2008) Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev; 60: 1209-1217.
44. Treat L.H., McDannold N., Vykhodtseva N., Zhang Y., Tam K., Hynynen K., (2007) Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI, guided focused ultrasound. Int J Cancer; 121: 901-907. (Pubitemid 47106223)
45. Watanabe W., Arakawa N., Matsunaga S., Higashi T., Fukui K., Isobe K., Itoh K., (2004) Femtosecond laser disruption of subcellular organelles in a living cell. Opt Express; 12: 4203-4213.
46. Chung S.H., Mazur E., (2009) Surgical applications of femtosecond lasers. J Biophotonics; 2: 557-572.
47. Tirlapur U.K., König K., (2002) Cell biology: targeted transfection by femtosecond laser. Nature; 418: 290-291. (Pubitemid 34790671)
48. Andresen V., Alexander S., Heupel W.-M., Hirschberg M., Hoffman R.M., Friedl P., (2009) Infrared multiphoton microscopy: subcellular-resolved deep tissue imaging. Curr Opin Biotechnol; 20: 54-62.
49. Tirlapur U.K., König K., Peuckert C., Krieg R., Halbhuber K.-J., (2001) Femtosecond near-infrared laser pulses elicit generation of reactive oxygen species in mammalian cells leading to apoptosis-like death. Exp Cell Res; 263: 88-97. (Pubitemid 32989109)
50. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol; 69: 29.
51. Vlieghe P., Khrestchatisky M., (2012) Medicinal chemistry based approaches and nanotechnology based systems to improve CNS drug targeting and delivery. Med Res Rev; 33: 457-516.
52. Peura L., Malmioja K., Laine K., LeppaÃànen J., Gynther M., Isotalo A., Rautio J., (2011) Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol Pharm; 8: 1857-1866.
53. Albert A., (1958) Chemical aspects of selective toxicity. Nature; 182: 421.
54. DiNunzio J.C., Williams R.O. III, (2008) CNS disorders-current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm; 34: 1141-1167.
55. Pavan B., Dalpiaz A., Ciliberti N., Biondi C., Manfredini S., Vertuani S., (2008) Progress in drug delivery to the central nervous system by the prodrug approach. Molecules; 13: 1035-1065.
56. Rautio J., Laine K., Gynther M., Savolainen J., (2008) Prodrug approaches for CNS delivery. AAPS J; 10: 92-102.
57. Anderson B.D., (1996) Prodrugs for improved CNS delivery. Adv Drug Deliv Rev; 19: 171-202. (Pubitemid 26191620)
58. Misra A., Ganesh S., Shahiwala A., Shah S.P., (2003) Drug delivery to the central nervous system: a review. J Pharm Pharm Sci; 6: 252-273. (Pubitemid 37207232)
59. Pardridge W.M., (2007) Blood-brain barrier delivery. Drug Discov Today; 12: 54-61. (Pubitemid 46014479)
60. Anand B.S., Dey S., Mitra A.K., (2002) Current prodrug strategies via membrane transporters/receptors. Expert Opin Biol Ther; 2: 607-620.
61. Gynther M., Laine K., Ropponen J., Leppänen J., Mannila A., Nevalainen T., Savolainen J., Järvinen T., Rautio J., (2008) Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem; 51: 932-936. (Pubitemid 351304700)
62. Gynther M., Ropponen J., Laine K., LeppaÃànen J., Haapakoski P., Peura L., Järvinen T., Rautio J., (2009) Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. J Med Chem; 52: 3348-3353.
63. Uchino H., Kanai Y., Wempe M.F., Chairoungdua A., Morimoto E., Anders M., Endou H., (2002) Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol; 61: 729-737. (Pubitemid 34273151)
64. Pinnen F., Cacciatore I., Cornacchia C., Mollica A., Sozio P., Cerasa L.S., Iannitelli A., Fontana A., Nasuti C., Di Stefano A., (2012) CNS delivery of l-dopa by a new hybrid glutathione-methionine peptidomimetic prodrug. Amino Acids; 42: 261-269.
65. Gynther M., Jalkanen A., Lehtonen M., Forsberg M., Laine K., Ropponen J., Leppänen J., Knuuti J., Rautio J., (2010) Brain uptake of ketoprofen-lysine prodrug in rats. Int J Pharm; 399: 121-128.
66. Bonina F., Puglia C., Rimoli M.G., Melisi D., Boatto G., Nieddu M., Calignano A., Rana G.L., Caprariis P., (2003) Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J Drug Target; 11: 25-36. (Pubitemid 36527393)
67. Bilsky E.J., Egleton R.D., Mitchell S.A., Palian M.M., Davis P., Huber J.D., Jones H., Yamamura H.I., Janders J., Davis T.P., (2000) Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J Med Chem; 43: 2586-2590. (Pubitemid 30437141)
68. Chapman C.D., Frey W.H., Craft S., Danielyan L., Hallschmid M., Schiöth H.B., Benedict C., (2012) Intranasal treatment of central nervous system dysfunction in humans. Pharm Res; 30: 2475-2484.
69. Dhuria S.V., Hanson L.R., Frey W.H., (2009) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci; 99: 1654-1673.
70. Reger M., Watson G., Green P., Wilkinson C., Baker L., Cholerton B., Fishel M., Plymate S., Breitner J., DeGroodt W., (2008) Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology; 70: 440-448.
71. Guastella A.J., Einfeld S.L., Gray K.M., Rinehart N.J., Tonge B.J., Lambert T.J., Hickie I.B., (2010) Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry; 67: 692-694.
72. Gavini E., Rassu G., Ciarnelli V., Spada G., Cossu M., Giunchedi P., (2012) Mucoadhesive drug delivery systems for nose-to-brain targeting of dopamine. J Nanoneurosci; 2: 47-55.
73. Lochhead J.J., Thorne R.G., (2011) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev; 64: 614-628.
74. Wong H.L., Wu X.Y., Bendayan R., (2011) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev; 64: 686-700.
75. Silva G.A., (2008) Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC Neurosci; 9: S4.
76. Sahoo S.K., Labhasetwar V., (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today; 8: 1112-1120. (Pubitemid 37547917)
77. Lc Cruz, Soares L.U., Costa T.D., Mezzalira G., da Silveira N.P., Guterres S.L.S., Pohlmann A.R., (2006) Diffusion and mathematical modeling of release profiles from nanocarriers. Int J Pharm; 313: 198-205.
78. Patel T., Zhou J., Piepmeier J.M., Saltzman W.M., (2011) Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev; 64: 701-705.
79. TheRoyalSociety. (2004) Nanoscience and nanotechnologies: opportunities and uncertainties. In: Clyvedon Press C, UK, editors. Nanoscience and Nanotechnologies: Opportunities and Uncertainties. London, UK: The Royal Society; p. 1-127.
80. Wong H.L., Rauth A.M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., Erhan S.Z., Wu X.Y., (2006) A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res; 23: 1574-1585. (Pubitemid 43993820)
81. Dawson M., Krauland E., Wirtz D., Hanes J., (2008) Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog; 20: 851-857. (Pubitemid 38784024)
82. Chen D.B., Yang T., Lu W.L., Zhang Q., (2001) In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull; 49: 1444-1447. (Pubitemid 33043274)
83. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., Weissleder R., (2000) Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol; 18: 410-414. (Pubitemid 30217528)
84. Chen P.Y., Liu H.L., Hua M.Y., Yang H.W., Huang C.Y., Chu P.C., Lyu L.A., Tseng I.C., Feng L.Y., Tsai H.C., (2010) Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro-oncology; 12: 1050-1060.
85. Temsamani J., Vidal P., (2004) The use of cell-penetrating peptides for drug delivery. Drug Discov Today; 9: 1012-1019. (Pubitemid 39574557)
86. Sanders W.S., Johnston C.I., Bridges S.M., Burgess S.C., Willeford K.O., (2011) Prediction of cell penetrating peptides by support vector machines. PLoS Comput Biol; 7: e1002101.
87. Jones A.T., Sayers E.J., (2012) Cell entry of cell penetrating peptides and tales of tails wagging dogs. J Control Release; 161: 582-591.
88. Sebbage V., (2009) Cell-penetrating peptides and their therapeutic applications. Bioscience Horizons; 2: 64-72.
89. Morris M.C., Deshayes S., Heitz F., Divita G., (2008) Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell; 100: 201-217. (Pubitemid 351517084)
90. Nasrollahi S.A., Taghibiglou C., Azizi E., Farboud E.S., (2012) Cell-penetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Des; 80: 639-646.
91. Heitz F., Morris M.C., Divita G., (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol; 157: 195-206.
92. Koren E., Torchilin V.P., (2012) Cell-penetrating peptides: breaking through to the other side. Trends Mol Med; 18: 385-393.
93. Zhang X., Wang F., (2012) Intracellular transduction and potential of Tat PTD and its analogs: from basic drug delivery mechanism to application. Expert Opin Drug Deliv; 9: 457-472.
94. Taghibiglou C., Martin H.G., Lai T.W., Cho T., Prasad S., Kojic L., Lu J., Liu Y., Lo E., Zhang S., (2009) Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat Med; 15: 1399-1406.
95. Johnson R.M., Harrison S.D., Maclean D., (2011) Therapeutic applications of cell-penetrating peptides. Methods Mol Biol; 683: 535-551.
96. Brust T.B., Cayabyab F.S., MacVicar B.A., (2007) C-Jun N-terminal kinase regulates adenosine A1 receptor-mediated synaptic depression in the rat hippocampus. Neuropharmacology; 53: 906-917. (Pubitemid 350137387)
97. Suhorutsenko J., Oskolkov N., Arukuusk P., Kurrikoff K., Eriste E., Copolovici D.M., Langel U., (2011) Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug Chem; 22: 2255-2262.